# Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma

> **NCT00906841** · PHASE2 · TERMINATED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 75 (actual)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** 90Y-DOTA-hLL2

## Key facts

- **NCT ID:** NCT00906841
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2016-03
- **Final completion:** 2018-04
- **Target enrollment:** 75 (ACTUAL)
- **Why stopped:** completed recruitment of patients on 15 december 2010
- **Last updated:** 2018-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00906841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00906841, "Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00906841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*